Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 28, Issue 5, Pages 1042-1049
Publisher
Springer Science and Business Media LLC
Online
2022-03-03
DOI
10.1038/s41591-022-01739-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
- (2022) Emma K. Accorsi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
- (2022) Nicole Wolter et al. LANCET
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
- (2022) Juan Manuel Carreño et al. NATURE
- SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
- (2022) Annika Rössler et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
- (2022) Rolando Pajon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022
- (2022) A. Danielle Iuliano et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021
- (2022) Amelia G. Johnson et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
- (2021) Jennifer M. Dan et al. SCIENCE
- A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
- (2021) Laurence Chu et al. VACCINE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2021) Ali Pormohammad et al. Vaccines
- Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
- (2021) Angela Choi et al. NATURE MEDICINE
- Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
- (2021) Kashif Ali et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- (2021) Hana M. El Sahly et al. NEW ENGLAND JOURNAL OF MEDICINE
- New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
- (2021) Eli S. Rosenberg et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
- (2021) Srinivas Nanduri et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021
- (2021) Ashley Fowlkes et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021
- (2021) Mark W. Tenforde et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
- (2021) Patrick Tang et al. NATURE MEDICINE
- Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
- (2021) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Plasma Neutralization of the SARS-CoV-2 Omicron Variant
- (2021) Fabian Schmidt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Towards a population-based threshold of protection for COVID-19 vaccines
- (2021) David Goldblatt et al. VACCINE
- The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
- (2021) Li Zhang et al. Emerging Microbes & Infections
- An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
- (2020) Lisa A. Jackson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
- (2020) Evan J. Anderson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- From Vaccines to Memory and Back
- (2010) Federica Sallusto et al. IMMUNITY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started